American Academy Of Family Physicians-Human Papillomavirus Vaccine-Urinary Tract Infections

HPV Vaccine Reducing Infections, Even Among Unvaccinated: Study

MONDAY, July 9 -- Even among unvaccinated girls and young women, the human papillomavirus vaccine is reducing infections of certain strains of the virus known to cause genital warts and cervical cancer, new research finds.The study is among the... read more..

source:http://drugs.com

More Proof Cranberry Juice Thwarts Infection

MONDAY, July 9 -- Cranberry juice and cranberry supplements really do help prevent urinary tract infections, a new study confirms.As many as 50 percent of women will develop at least one urinary tract infection in their lifetime, and up to 30... read more..

source:http://drugs.com

Health Tip: Be a Safe Biker

-- Though biking is great exercise, and can keep you in shape and help you lose weight, you should still take precautions to help prevent injury.The American Academy of Family Physicians offers these safety tips for cyclists:Protect your eyes... read more..

source:http://drugs.com

Cervical Intraepithelial Neoplasia-Human Papillomavirus-Prophylactic Vaccine-Dendritic Cells

HPV DNA vax should enter the clinic in 2013

Vaccibody's lead therapeutic DNA vaccine, developed for the treatment of precancerous changes in the cervix caused by human papillomavirus (HPV) infection, is expected to move into the clinic in late 2013 once funding is in place, the company CEO Ole Henrik Brekke told FierceVaccines  at BIO 2012. The trial will recruit women who are infected with HPV-16 and have cervical intraepithelial neoplasia (CIN) at grade 1 or 2.The Norwegian vaccine company has designed the vaccine to trigger a T cell response in a single shot by targeting the dendritic cells (also known as antigen-presenting cells). The HPV vaccine is administered just under the skin or into the muscle using electroporation technology, where a small charge allows the plasmid (a small circle of coding DNA) into the cell. The genetic information then harnesses the cell's manufacturing capabilities to create the three-component protein vaccine."We see a higher immune response than other DNA vaccines in animal studies, and it doesn't need an adjuvant," says Brekke. "We think that this is because the vaccine molecules adhere to the dendritic cells."Future formulations of the vaccine could use needle-free administration techniques. The technology also has potential for infectious disease and in veterinary use, as a prophylactic vaccine, and the company is in discussion with a number of potential partners, according to Brekke.- read the company overview at BIO 2012Related Articles:
GeoVax: Meeting the HIV vaccine challenge
DNA vaccine swats TB and HIV
Army uses ducks and DNA vax to make antivirals
Scancell's DNA melanoma vaccine poised for Phase II
DNA vaccine for prostate cancer moves into Phase III read more..

source:http://www.fiercevaccines.com

Government Of India-Cervical Cancer-Clinical Trial-Andhra Pradesh-Hpv Vaccine

Controversy halts HPV vax trial in India

Human papillomavirus infection is the cause of nearly all cases of cervical cancer, and so immunizing young women before they are exposed to the virus could save a great many lives. So, the idea of a large scale clinical trial of an HPV vaccine in India seems like a valid idea, based on the country's supposed huge cervical cancer healthcare burden. Not so--according to a paper published in the Journal of the Royal Society of Medicine, the epidemiology behind the study is flawed and the trial is currently the subject of an investigation by the Indian government.The trial was under the auspices of PATH, an international health charity, and included over 23,000 girls in the Indian states of Gujarat and Andhra Pradesh. The charity had claimed that "in raw numbers, India has the largest burden of cancer of the cervix of any country worldwide." However, according to the study, led by Allyson Pollock of Barts and The London Medical School, the cancer surveillance, registration and monitoring in India in general, particularly in the Gujarat and Andhra Pradesh regions, were incomplete, so that it would be impossible to tell whether the vaccine would be successful in preventing the disease.The figures that do exist for India show that there were only 22 cases of cervical cancer per 100,000 in 2004/2005 in india, falling from 43 cases per 100,000 in 1982/1983--this is around half the rate in countries like Brazil and Zimbabwe."This trial has clearly raised serious concerns for the people and government of India," says Pollock. "We found that current data on cervical cancer incidence do not support PATH's claim that India has a large burden of cervical cancer or its decision to roll out the vaccine program."India does have major health burdens, for example in malaria and other infectious diseases, maternal anemia and malnutrition, and so the use of an expensive HPV vaccine, which is one of the more expensive vaccines on the market, for a health issue with a lower impact would seem to be a flawed use of limited financial resources.- read the press release
- see the paperRelated Articles:
GAVI Alliance could be closer to HPV vax deal
Gardasil could cut cancer in women already infected with HPV
Study: Most girls who get HPV vax say they see need to practice safe sex read more..

source:http://www.fiercevaccines.com

Cervical Cancer Vaccine-Human Papillomavirus-Gavi Alliance-Hpv Vaccines

GAVI Alliance could be closer to HPV vax deal

In November, the GAVI Alliance, a public-private partnership focused on saving lives and protecting health by increasing access to immunization, announced that it would look to introduce human papillomavirus (HPV) and rubella vaccines in developing countries. This seems to have come a step closer to reality, as, according to Reuters, GAVI is nearing a price deal with vaccine rivals GlaxoSmithKline ($GSK) and Merck ($MRK) for Gardasil and Cervarix. This could cut the more than 200,000 deaths from cervical cancer that occur every year in the developing world.A spokesperson for GAVI told Reuters that "at least one" of these pharmaceutical companies had made "encouraging progress towards an acceptable price" for GAVI-eligible countries, but hasn't identified the company.GSK was one of the first manufacturers to sign up to the alliance, agreeing to supply up to 300 million doses of its vaccine Synflorix for invasive pneumococcal disease. A GSK spokesperson has confirmed to Reuters that the company is in negotiation with GAVI over cervical cancer vaccine provision, adding that "GSK is committed to offering the lowest prices for its vaccines to the poorest countries.""The HPV vaccine is critical to women and girls in poorer countries because they usually do not have access to screening to prevent cervical cancer and treatment taken for granted in richer nations. Today, we have taken deliberate first steps to correct this inequity," said Dr. Seth Berkley, CEO of GAVI.If negotiations are successful and the vaccine can be delivered successfully to people in the developing countries, up to 2 million women and girls in 9 countries could be protected from cervical cancer by 2015.- read the article in ReutersRelated Articles:
Pfizer, GSK to provide more discount vaccines for GAVI
GAVI to bring HPV vaccines to poor countries
GAVI board hit with conflict of interest woes
GAVI Alliance pours $100M into meningitis vaccine
GSK under fire for delay of new vax program read more..

source:http://www.fiercevaccines.com

International Research Group-Cruciferous Vegetables-Breast Cancer Survival-Human Papillomavirus

Preteens More Likely to Report HPV Vaccine Side Effects

TUESDAY, April 3 -- A new study finds that preteen girls are more likely than older teens and adult women to experience side effects after receiving the human papillomavirus (HPV) vaccine, Gardasil.However, the side effects are not serious and are... read more..

source:http://drugs.com

Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study

TUESDAY, April 3 -- Eating broccoli, one of the top "super foods," and other cruciferous vegetables may improve your odds for breast cancer survival, a new study suggests.In a study of women in China diagnosed with breast cancer, researchers found... read more..

source:http://drugs.com

Taller, Heavier Women May Face Higher Ovarian Cancer Risk

TUESDAY, April 3 -- Taller, heavier women may be at an increased risk of ovarian cancer, research suggests.An international research group examined data from 47 studies conducted in 14 countries involving more than 25,000 women with ovarian cancer... read more..

source:http://drugs.com